Eli Lilly (LLY) Prepaid Assets (2009 - 2026)
Eli Lilly (LLY) posted Prepaid Assets of $214.0 million for Q1 2026, down 98.51% quarter-over-quarter from $14.3 billion in Q4 2025, and down 98.54% year-on-year from $14.7 billion in Q1 2025.
Eli Lilly (LLY) Prepaid Assets (2009 - 2026) Analysis & Trends
Eli Lilly (LLY) has reported Prepaid Assets for 18 consecutive years, with $214.0 million the latest figure, recorded in Q1 2026.
- Prepaid Assets for Q1 2026 came in at $214.0 million, down 98.54% year-over-year; the trailing twelve-month figure through Mar 2026 was $214.0 million (down 98.54% YoY), and the FY2025 annual result was $14.3 billion, up 5281.58% from the prior year.
- Prepaid Assets was $214.0 million for Q1 2026 at Eli Lilly, down from $14.3 billion in the prior quarter.
- Over five years, Prepaid Assets peaked at $20.2 billion in Q3 2025 and troughed at $7.3 million in Q4 2022.
- Average Prepaid Assets over 5 years is $4.6 billion, with a median of $2.7 billion recorded in 2022.
- Year-over-year, Prepaid Assets sank 99.71% in 2022 and surged 14943.61% in 2025.
- Over 5 years, Prepaid Assets stood at $7.3 million in 2022, then soared by 1947.95% to $149.5 million in 2023, then jumped by 77.93% to $266.0 million in 2024, then jumped by 5281.58% to $14.3 billion in 2025, then sank by 98.51% to $214.0 million in 2026.
- Per Business Quant data, the three most recent Prepaid Assets figures were $214.0 million in Q1 2026, $14.3 billion in Q4 2025, and $20.2 billion in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - |
| 10 | Biogen | 30.87 Bn | 26.59 Bn | 1.82 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 214.00 Mn |
| Dec 31, 2025 | 14.32 Bn |
| Sep 30, 2025 | 20.25 Bn |
| Jun 30, 2025 | 68.80 Mn |
| Mar 31, 2025 | 14.65 Bn |
| Dec 31, 2024 | 266.00 Mn |
| Sep 30, 2024 | 134.60 Mn |
| Jun 30, 2024 | 142.20 Mn |
| Mar 31, 2024 | 6.35 Bn |
| Dec 31, 2023 | 149.50 Mn |
| Sep 30, 2023 | 5.25 Bn |
| Jun 30, 2023 | 4.53 Bn |
| Mar 31, 2023 | 3.58 Bn |
| Dec 31, 2022 | 7.30 Mn |
| Sep 30, 2022 | 2.74 Bn |
| Jun 30, 2022 | 2.81 Bn |
| Mar 31, 2022 | 2.70 Bn |
| Dec 31, 2021 | 2.53 Bn |
| Sep 30, 2021 | 3.05 Bn |
| Jun 30, 2021 | 3.30 Bn |